Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Squamous Cell Carcinoma of Head and Neck 22Lung Neoplasms 22Oropharyngeal Neoplasms 14Nasopharyngeal Carcinoma 13Carcinoma 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 8Head and Neck Neoplasms 8Mouth Neoplasms 6Laryngeal Neoplasms 6Small Cell Lung Carcinoma 5Neoplasms 5Hypopharyngeal Neoplasms 5Cholangiocarcinoma 5Biliary Tract Neoplasms 5Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoid Interstitial Pneumonia 3Lung Diseases 3Carcinoma, Transitional Cell 3Carcinoma, Squamous Cell 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3

Interventions

Cyclophosphamide 9fludarabine 7Dexamethasone 7pomalidomide 6Rituximab 6pembrolizumab 5selinexor 4obinutuzumab 4glofitamab 4Lenalidomide 4daratumumab 3belantamab mafodotin 3Temozolomide 3Gemcitabine 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2fludarabine phosphate 2enzalutamide 2cemiplimab 2carfilzomib 2abemaciclib 2PF06821497 2Mesna 2Lisaftoclax 2Injections 2Immunotherapy, Adoptive 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Cisplatin × 30 days × Clear all
NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡